Juan Gómez Rivas/icua.es
Apr 5, 2025, 16:48
Juan Gómez Rivas: Briganti 2023 Nomogram Spares 47% of Unnecessary ePLNDs in Prostate Cancer
Juan Gómez Rivas, Associate Professor at The Complutense University of Madrid, shared a post on X:
“Smarter staging in prostate cancer?
In patients with intermediate/high-risk prostate cancer and negative PSMA PET (miN0), extended pelvic lymph node dissection (ePLND) remains a clinical dilemma.
This multi-institutional study (n = 282) externally validated five nomograms to predict lymph node invasion (LNI):
- MSKCC
- Briganti 2017
- Briganti 2019
- Amsterdam-Brisbane-Sydney
- Briganti 2023
Key finding:
The Briganti 2023 nomogram outperformed all others with highest accuracy (C-index: 77%) and spared 47% of unnecessary ePLNDs at a 5% cutoff—while missing only 3.8% of LNI cases!
Clinical implications:
- Negative PSMA PET ≠ no risk: ~13% still had LNI!
- Micrometastases matter: PSMA PET may miss them due to spatial resolution limits.
- Briganti 2023 helps tailor who really needs nodal dissection, balancing risks and benefits.”
External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography
Authors: Giorgio Gandaglia, Alberto Briganti, et al.
More posts featuring Juan Gómez Rivas.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 5, 2025, 16:31
Apr 5, 2025, 16:02